PRME
Prime Medicine, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.09
P/S
129.41
EV/EBITDA
-3.33
DCF Value
$-0.10
FCF Yield
-27.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-58.1%
Operating Margin
-4498.1%
Net Margin
-4342.4%
ROE
-178.6%
ROA
-58.7%
ROIC
-66.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $838.0K | $-46.1M | $-0.26 |
| FY 2025 | $4.6M | $-201.1M | $-1.35 |
| Q3 2025 | $1.2M | $-50.6M | $-0.32 |
| Q2 2025 | $1.1M | $-52.6M | $-0.41 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.67
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.